Hi Jill
I posted a question to you on Twitter / X, hoping I could use the 2 slides you prepared that Ben Solomon (a work colleague of mine) used at the ASCO AM this year
Thanks for letting me know
Michael
Dear Ms. Feldman,
I’m a producer working with SBS-TV, one of the top three broadcasting networks, in South Korea. We would love to interview you for a documentary about a new therapy involving Lazcluze you commented in “ FDA Approves Johnson & Johnson’s Rybrevant and Lazcluze for Advanced Non-Small Cell Lung Cancer.”
Have you been treated with this new therapy? Do you know patients who have benefited from the MARIPOSA trial?
Look forward to your reply. We would like to interview you early next week. You can call me at 347-330-0290 to discuss further. Many thanks. Sabina
Hi Jill
I posted a question to you on Twitter / X, hoping I could use the 2 slides you prepared that Ben Solomon (a work colleague of mine) used at the ASCO AM this year
Thanks for letting me know
Michael
Dear Ms. Feldman,
I’m a producer working with SBS-TV, one of the top three broadcasting networks, in South Korea. We would love to interview you for a documentary about a new therapy involving Lazcluze you commented in “ FDA Approves Johnson & Johnson’s Rybrevant and Lazcluze for Advanced Non-Small Cell Lung Cancer.”
Have you been treated with this new therapy? Do you know patients who have benefited from the MARIPOSA trial?
Look forward to your reply. We would like to interview you early next week. You can call me at 347-330-0290 to discuss further. Many thanks. Sabina